Monica M. Bertagnolli, MD, FACS, FASCO
Due to major advancements made within the past year in the development of new therapies for patients with difficult-to-treat, rare cancers, ASCO has selected progress in treating rare cancers as its Advance of the Year.1
ASCO made the announcement as part of Clinical Cancer Advances 2019: ASCO’s Annual Report on Progress Against Cancer
. The annual update on oncology treatment highlights the most impactful clinical research milestones and policy developments that have been achieved over the past year.
ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, said in a press release that when it comes to furthering the progress made in the cancer space as a whole, especially in rare cancers where there is a great deal of unmet need, federal investment is critical.
... to read the full story